Now Playing
Opinion|Videos|April 14, 2025
Exploring Updates From KEYNOTE-799 at ELCC 2025
Panelists discuss how KEYNOTE-799 provides updated data on safety, toxicity, positive response rates, and median survival rates for both squamous and nonsquamous non–small cell lung cancer treatments.
Advertisement
Advertisement
Related to this article
FDA final guidance sets a risk-based potency assurance roadmap for cell and gene therapies, spanning development, manufacturing controls, lot release assays, and monitoring.
SABR had higher 3-year all-cause mortality than surgery in early-stage NSCLC (30.3% vs 21.6%) in an emulated target trial; the gap narrowed at age 80 and older.
Hoth Therapeutics stopped the phase 2a CLEER-001 trial of topical HT-001 early after an interim review and will seek FDA input on phase 3.
Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.
Updated ENZARAD findings show no significant metastasis-free survival benefit with enzalutamide, although patients receiving pelvic lymph node radiation may benefit from intensification.
Short-course neoadjuvant botensilimab plus balstilimab drives deep responses in resectable pMMR and dMMR colon cancer, with ctDNA clearance and no recurrences.
The FDA granted final approval to Alembic's generic venetoclax tablets, rated therapeutically equivalent to Venclexta, for CLL/SLL and newly diagnosed AML.
Lauren Banks, MD, PhD, explains early findings from a pilot study of lifileucel in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma, including treatment feasibility, safety, and response durability.
Advertisement
Advertisement
Trending on Targeted Onc
1
A New Era in Sarcoma Treatment? Dr Banks on the Potential of TIL Therapy
2
FDA Finalizes Potency Guidance for Cell and Gene Therapy Products
3
FDA Approves Generic Venetoclax Tablets for CLL/SLL and AML
4
Enzalutamide Fails to Improve Survival in High-Risk Prostate Cancer
5